For example, rash was reported in 43% (6% grade ≥3) of patients receiving amivantamab plus chemotherapy compared with 64% (17% grade ≥3) of patients receiving amivantamab plus lazertinib.16,28 Likewise, paronychia was reported in 37% of patients treated with amivantamab plus chemotherapy and 69% of patients treated with amivantamab plus lazertinib.16,28 The results across these 2 studies suggest that cutaneous AEs with amivantamab are exacerbated by the addition of lazertinib (or potentially EGFR-targeted therapy in general) compared with chemotherapy agents with non-overlapping AE profiles. The gene discussed is EGFR; the disease is paronychia.